Paul Harrison

Dr. Paul Harrison

orcid

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 November 2018 in Journal of Extracellular Vesicles
Verified
Journal Article
Open access
CTClotilde Théry
Clotilde Théry
KWKenneth Witwer
Kenneth Witwer
EAElena Aikawa
Elena Aikawa
MAMaria Jose Alcaraz
Maria Jose Alcaraz
JAJohnathon Anderson
Johnathon Anderson
Ewa Zuba-SurmaEwa Zuba-Surma
Ewa Zuba-Surma
The last decade has seen a sharp increase in the number of scientific publications describing physiological and pathological functions of extracellular vesicles (EVs), a collective term covering various subtypes of cell‐released, membranous structures, called exosomes, microvesicles, microparticles, ectosomes, oncosomes, apoptotic bodies, and many other names. However, specific issues arise when working with these entities, whose size and amount often make them difficult to obtain as relatively pure preparations, and to characterize properly. The International Society for Extracellular Vesicles (ISEV) proposed Minimal Information for Studies of Extracellular Vesicles (“MISEV”) guidelines for the field in 2014. We now update these “MISEV2014” guidelines based on evolution of the collective knowledge in the last four years. An important point to consider is that ascribing a specific function to EVs in general, or to subtypes of EVs, requires reporting of specific information beyond mere description of function in a crude, potentially contaminated, and heterogeneous preparation. For example, claims that exosomes are endowed with exquisite and specific activities remain difficult to support experimentally, given our still limited knowledge of their specific molecular machineries of biogenesis and release, as compared with other biophysically similar EVs. The MISEV2018 guidelines include tables and outlines of suggested protocols and steps to follow to document specific EV‐associated functional activities. Finally, a checklist is provided with summaries of key points.

1 July 2012 in Pharmacological Reviews
Verified
Journal Article
Closed access
EPEdwin van der Pol
Edwin van der Pol
ABAnita N. Böing
Anita N. Böing
PHPaul Harrison
Paul Harrison
ASAugueste Sturk
Augueste Sturk
RNRienk Nieuwland
Rienk Nieuwland
Both eukaryotic and prokaryotic cells release small, phospholipid-enclosed vesicles into their environment. Why do cells release vesicles? Initial studies showed that eukaryotic vesicles are used to remove obsolete cellular molecules. Although this release of vesicles is beneficial to the cell, the vesicles can also be a danger to their environment, for instance in blood, where vesicles can provide a surface supporting coagulation. Evidence is accumulating that vesicles are cargo containers used by eukaryotic cells to exchange biomolecules as transmembrane receptors and genetic information. Because also bacteria communicate to each other via extracellular vesicles, the intercellular communication via extracellular cargo carriers seems to be conserved throughout evolution, and therefore vesicles are likely to be a highly efficient, robust, and economic manner of exchanging information between cells. Furthermore, vesicles protect cells from accumulation of waste or drugs, they contribute to physiology and pathology, and they have a myriad of potential clinical applications, ranging from biomarkers to anticancer therapy. Because vesicles may pass the blood-brain barrier, they can perhaps even be considered naturally occurring liposomes. Unfortunately, pathways of vesicle release and vesicles themselves are also being used by tumors and infectious diseases to facilitate spreading, and to escape from immune surveillance. In this review, the different types, nomenclature, functions, and clinical relevance of vesicles will be discussed.

1 December 2011 in Nanomedicine: Nanotechnology, Biology and Medicine
Verified
Journal Article
Open access
RDRebecca A. Dragovic
Rebecca A. Dragovic
CGChristopher Gardiner
Christopher Gardiner
ABAlexandra S. Brooks
Alexandra S. Brooks
DTDionne S. Tannetta
Dionne S. Tannetta
DFDavid Ferguson
David Ferguson
ISIan L. Sargent
Ian L. Sargent
Cellular microvesicles and nanovesicles (exosomes) are involved in many disease processes and have major potential as biomarkers. However, developments in this area are constrained by limitations in the technology available for their measurement. Here we report on the use of fluorescence nanoparticle tracking analysis (NTA) to rapidly size and phenotype cellular vesicles. In this system vesicles are visualized by light scattering using a light microscope. A video is taken, and the NTA software tracks the brownian motion of individual vesicles and calculates their size and total concentration. Using human placental vesicles and plasma, we have demonstrated that NTA can measure cellular vesicles as small as ≈ 50 nm and is far more sensitive than conventional flow cytometry (lower limit ≈ 300 nm). By combining NTA with fluorescence measurement we have demonstrated that vesicles can be labeled with specific antibody-conjugated quantum dots, allowing their phenotype to be determined. The authors of this study utilized fluorescence nanoparticle tracking analysis (NTA) to rapidly size and phenotype cellular vesicles, demonstrating that NTA is far more sensitive than conventional flow cytometry.

1 July 2014 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
EPE. van der Pol
E. van der Pol
FCF. A. W. Coumans
F. A. W. Coumans
AGA. E. Grootemaat
A. E. Grootemaat
CGC. Gardiner
C. Gardiner
ISI. L. Sargent
I. L. Sargent
RNR. Nieuwland
R. Nieuwland

10 April 2013 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
PDF file
MCMarco Cattaneo
Marco Cattaneo
CCChiara Cerletti
Chiara Cerletti
PHPaul Harrison
Paul Harrison
CHC. P. M. Hayward
C. P. M. Hayward
DKD. Kenny
D. Kenny
AMA. D. Michelson
A. D. Michelson
Click on the article title to read more.

26 July 2011 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
PHPaul Harrison
Paul Harrison
IMIan Mackie
Ian Mackie
AMAndrew Mumford
Andrew Mumford
CBCarol Briggs
Carol Briggs
RLRi Liesner
Ri Liesner
BHBritish Committee for Standards in Haematology
British Committee for Standards in Haematology